CN113321594B - Oxidative coupling rearrangement product based on tryptamine skeleton and preparation method and application thereof - Google Patents
Oxidative coupling rearrangement product based on tryptamine skeleton and preparation method and application thereof Download PDFInfo
- Publication number
- CN113321594B CN113321594B CN202110716979.2A CN202110716979A CN113321594B CN 113321594 B CN113321594 B CN 113321594B CN 202110716979 A CN202110716979 A CN 202110716979A CN 113321594 B CN113321594 B CN 113321594B
- Authority
- CN
- China
- Prior art keywords
- raw material
- preparation
- tryptamine
- solution
- ome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an oxidative coupling rearrangement product based on a tryptamine skeleton and a preparation method and application thereof. The invention realizes the terminal functionalization of the tryptamine derivatives through mild reaction conditions. The preparation method is simple, the reaction condition is mild, the yield is high, the practicability is high, and the relative molecular mass of the synthesized compound is about 300. The skeleton structure is synthesized for the first time, has obvious antitumor activity, and can be used for developing medicaments for treating lung adenocarcinoma, lung cancer and cervical cancer.
Description
Technical Field
The invention belongs to the field of medicinal chemistry, and particularly relates to an oxidative coupling rearrangement product based on a tryptamine skeleton, and a preparation method and application thereof.
Background
Indole alkaloids are one of the largest and most important medicinal categories in alkaloid natural products, and can be applied to treating common diseases such as liver diseases, lung diseases and the like. Because indole derivatives are ubiquitous in various natural products, receptors, proteins and drug molecules, the indole derivatives are indispensable components in organic synthesis and pharmaceutical research, and are always hot research points in the fields of natural product synthesis, new drug research and development and the like. Wherein the tryptamine derivatives have a wide range of biological activities.
According to the invention, a tryptamine skeleton-based oxidative coupling rearrangement product is obtained through an oxidative coupling rearrangement reaction, a tryptamine compound is oxidized by using sodium periodate to obtain a corresponding dicarbonyl compound, then the dicarbonyl compound and an aniline compound are subjected to a coupling rearrangement reaction, and terminal functionalization is carried out on the tryptamine derivative through a mild reaction condition.
Disclosure of Invention
The invention aims to provide an oxidative coupling rearrangement product based on a tryptamine skeleton, and a preparation method and application thereof, wherein the preparation method is simple, the experimental conditions are mild, harsh conditions such as high pressure, strong acid and strong base are not required, and the reaction yield is high (generally over 50%).
In order to achieve the purpose, the invention adopts the following technical scheme:
an oxidative coupling rearrangement product based on tryptamine skeleton has the following structure:
wherein R is 1 H, Cl or OMe, R 2 H, Cl or OMe.
The preparation method comprises the following steps: dissolving a raw material B in thionyl chloride, adding trifluoroacetic acid and dimethyl sulfoxide to react for 6-15h at 100 ℃ to obtain the oxidation coupling rearrangement product based on the tryptamine skeleton;
the structural general formula of the raw material B is as follows:
wherein R is 1 H, Cl or OMe.
R in the raw material B 1 The preparation of H or OMe comprises the following steps: dissolving sodium periodate in water, and stirring for 1 hour at 0 ℃ to prepare a solution I; mixing the raw material A:
wherein R is 1 Dissolving H or OMe in methanol to obtain solution II; slowly adding the solution I into the solution II, reacting for 15 hours at room temperature, pouring the obtained mixture into water, and extracting for 2-3 times by using dichloromethane; the organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting crude product was purified by silica gel Chromatography (CH) 2 Cl 2 MeOH ═ 30:1) purification afforded starting material B.
R in the raw material B 1 The preparation of Cl comprises the following steps: mixing the raw material A:
wherein R is 1 Dissolving Cl in dichloromethane, and adding cuprous chloride and pyridine; the reaction was stirred at room temperature under an oxygen atmosphere, and the resulting mixture was diluted with dichloromethane and washed with water and saturated brine; separating organic layer, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, and subjecting the obtained crude product to silica gel Chromatography (CH) 2 Cl 2 MeOH ═ 30:1) purification afforded starting material B.
The tryptamine skeleton-based oxidative coupling rearrangement product is applied to the preparation of medicines for treating lung adenocarcinoma, lung cancer and cervical cancer.
The invention has the beneficial effects that:
(1) the method has the advantages of mild reaction conditions, simple operation, controllable product position selection, strong operability, strong practicability, no requirement of harsh conditions such as high pressure, strong acid and strong alkali, short reaction time and high yield of over 50 percent generally.
(2) The molecular weight of the synthesized oxidation coupling rearrangement product with the tryptamine skeleton structure is small, generally about 300, and the method is expected to be used for preparing related cancer treatment medicines, and simultaneously provides a new solution and scheme for the synthesis of other similar compounds.
Detailed Description
In order to make the present invention more comprehensible, the technical solutions of the present invention are further described below with reference to specific embodiments, but the present invention is not limited thereto.
EXAMPLE 1 preparation of Compound 1
(1) Raw material B 1 Preparation of
6.33g of sodium periodate was dissolved in 150mL of water and stirred at 0 ℃ for 1 hour to prepare a solution I. 1.5g A 1 Dissolved in 150mL of methanol to obtain solution II. Solution I was slowly added to solution II. After removal of the ice bath, the reaction was stirred at room temperature for 15 hours. The reaction mixture was then poured into 100mL of water and extracted 2 times with 50mL of dichloromethane, respectively. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting crude product was purified by silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) to give compound B 1 (970mg，58％)。
Physical state: a white solid.
Melting point: 107.5-108.3 ℃.
TLC：R f ＝0.23(EtOAc).
1 H NMR(500MHz,CDCl 3 )δ11.56(s,1H),8.74(d,J＝10.0Hz,1H),8.50(s,1H),7.91(d,J＝8.0Hz,1H),7.57(t,J＝7.8Hz,1H),7.17(t,J＝7.6Hz,1H),6.13(s,1H),3.66–3.63(m,2H),3.30(t,J＝5.6Hz,2H),1.96(s,3H).
13 C NMR(126MHz,CDCl 3 )δ203.68,170.46,159.96,139.86,135.51,131.01,123.38,121.67,121.54,39.59,34.53,23.37.
(2) Preparation of Compound 1
117mg of B 1 Dissolve in 3mL of thionyl chloride and add 91. mu.L of aniline and 37. mu.L of trifluoroacetic acid. The reaction was stirred at 100 ℃ for 8 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. The organic layer was washed with 30mL of water and saturated 30mL of brine, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting crude product was chromatographed on silica gel (CH) 2 Cl 2 Purification with/MeOH ═ 30:1) afforded compound 1(80mg, 55%)。
Physical state: a pale yellow solid.
Melting point: 185.4-186.1 deg.C
TLC：R f ＝0.52(CH 2 Cl 2 /MeOH＝10:1).
1 H NMR(500MHz,DMSO-d 6 )δ8.77–8.70(m,2H),8.57(s,1H),7.98(d,J＝8.1Hz,1H),7.87(d,J＝7.9Hz,1H),7.68(s,1H),7.45(s,1H),7.17(s,3H),6.82(s,2H),6.67(d,J＝6.8Hz,2H),4.33–4.25(m,2H),1.85(s,3H).
13 C NMR(126MHz,CDCl 3 )δ172.03,152.71,149.21,146.71,144.93,129.72,129.17,129.12,126.05,125.47,123.18,122.01,121.13,117.63,38.74,22.98。
EXAMPLE 2 preparation of Compound 2
(1) Raw material B 1 Preparation of
See example 1.
(2) Preparation of Compound 2
140mg of B 1 Dissolved in 4mL of thionyl chloride, 135. mu.L of 3-methoxyaniline and 44. mu.L of trifluoroacetic acid were added. The reaction was stirred at 100 ℃ for 7 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. The organic layer was washed with 30mL of water and 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel Chromatography (CH) 2 Cl 2 purification/MeOH ═ 30:1) afforded compound 2(108mg, 56%).
Physical state: green solid.
Melting point: 155.7-156.4 ℃.
TLC：R f ＝0.30(CH 2 Cl 2 /MeOH＝20:1).
1 H NMR(500MHz,CDCl 3 )δ8.76(s,1H),8.57(s,1H),8.01(d,J＝8.1Hz,1H),7.89–7.86(m,1H),7.66–7.62(m,1H),7.36–7.30(m,2H),7.09(t,J＝8.1Hz,1H),6.49–6.46(m,1H),6.44–6.41(m,1H),6.36(t,J＝2.2Hz,1H),4.51(d,J＝6.6Hz,2H),3.69(s,3H),2.03(s,3H).
13 C NMR(126MHz,CDCl 3 )δ171.99,160.55,152.49,148.99,146.69,146.32,129.93,129.80,128.92,126.06,125.59,123.41,122.31,110.35,106.68,103.43,55.29,38.72,22.95。
EXAMPLE 3 preparation of Compound 3
(1) Raw material B 1 Preparation of
See example 1.
(2) Preparation of Compound 3
Mixing 117mg of B 1 Dissolved in 3m L thionyl chloride and 128mg 4-chloroaniline and 37. mu.L trifluoroacetic acid were added. The reaction was stirred at 100 ℃ for 10 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. The organic layer was washed with 30mL of water and 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) afforded compound 3(45mg, 28%).
Physical state: a pale green solid.
Melting point: 193.4-194.2 ℃.
TLC：R f ＝0.34(CH 2 Cl 2 /MeOH＝20:1).
1 H NMR(500MHz,CDCl 3 )δ8.86(s,1H),8.58(s,1H),8.02(d,J＝8.2Hz,1H),7.80–7.78(m,1H),7.67–7.63(m,1H),7.37–7.33(m,1H),7.19–7.15(m,1H),7.15–7.12(m,2H),6.76–6.73(m,2H),4.51(d,J＝6.6Hz,2H),2.03(s,3H).
13 C NMR(126MHz,CDCl 3 )δ172.03,152.52,149.18,146.34,143.58,129.86,129.25,129.09,125.83,125.78,125.71,123.00,122.15,118.61,38.80,22.97。
EXAMPLE 4 preparation of Compound 4
(1) Raw material B 1 System of (1)Is provided with
See example 1.
(2) Preparation of Compound 4
Mixing 117mg of B 1 Dissolved in 3m L thionyl chloride and 143mg of 1-naphthylamine and 37. mu.L of trifluoroacetic acid were added. The reaction was stirred at 100 ℃ for 6 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. The organic layer was washed with 30mL of water and 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude product, which was purified by silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) afforded compound 4(55mg, 32%).
Physical state: light grey solid.
Melting point: 217.4-218.6 ℃.
TLC：R f ＝0.32(CH 2 Cl 2 /MeOH＝20:1).
1 H NMR(500MHz,DMSO-d 6 )δ9.16(s,1H),8.80(s,1H),8.75(t,J＝6.0Hz,1H),8.51(d,J＝8.2Hz,1H),7.99(d,J＝8.3Hz,1H),7.93(d,J＝7.9Hz,1H),7.67(d,J＝8.5Hz,1H),7.65–7.63(m,1H),7.63–7.60(m,1H),7.60–7.57(m,1H),7.46(d,J＝8.2Hz,1H),7.35–7.32(m,1H),7.17(t,J＝7.8Hz,1H),6.27(d,J＝7.4Hz,1H),4.33(s,2H),1.86(s,3H).
13 C NMR(126MHz,DMSO-d 6 )δ171.28,153.19,149.01,145.77,142.06,134.74,129.90,129.60,128.70,126.89,126.52,126.21,126.07,125.81,124.93,124.46,123.71,122.90,121.18,112.38,38.06,22.80。
EXAMPLE 5 preparation of Compound 5
(1) Raw material B 2 Preparation of
2.56g of sodium periodate was dissolved in 60mL of water and then stirred at 0 ℃ for 1 hourThen, a solution I was prepared. 697mg of A 2 Dissolve in 60mL of methanol to obtain solution II. The solution was slowly added to solution II. After removal of the ice bath, the reaction was stirred at room temperature for 12 hours. The resulting mixture was then poured into 50mL of water and then extracted with 80mL of dichloromethane. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting crude product was purified by silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) to give compound B 2 (405mg，51％)。
Physical state: a pale yellow solid.
Melting point: 137.7-138.3 ℃.
TLC：R f ＝0.49(CH 2 Cl 2 /MeOH＝20:1).
1 H NMR(500MHz,CDCl 3 )δ11.18(s,1H),8.61(d,J＝9.2Hz,1H),8.39(s,1H),7.34(d,J＝2.5Hz,1H),7.11–7.07(m,1H),6.28(s,1H),3.80(s,3H),3.61(q,J＝5.6Hz,2H),3.24(t,J＝5.6Hz,2H),1.94(s,3H).
13 C NMR(126MHz,CDCl 3 )δ203.36,170.46,159.53,154.99,133.23,123.23,122.78,120.80,115.63,55.80,39.69,34.58,23.34.
(2) Preparation of Compound 5
Mixing 132mg of B 2 Dissolve in 3mL of thionyl chloride and add 112. mu.L of methoxyaniline and 37. mu.L of trifluoroacetic acid. The reaction was stirred at 100 ℃ for 9 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. The organic layer was washed with 30mL of water and 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a crude product, which was purified by silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) afforded compound 5(82mg, 47%).
Physical state: grey solid.
Melting point: 173.5-174.3 ℃.
TLC：R f ＝0.34(CH 2 Cl 2 /MeOH＝20:1)。
1 H NMR(500MHz,CDCl 3 )δ8.69(s,1H),8.49(s,1H),7.92(d,J＝9.2Hz,1H),7.29(dd,J＝9.2,2.8Hz,1H),7.10(d,J＝8.1Hz,1H),7.07(d,J＝4.1Hz,1H),7.06–7.04(m,1H),6.47–6.44(m,1H),6.40–6.37(m,1H),6.36(t,J＝2.2Hz,1H),4.51(d,J＝6.5Hz,2H),3.71(s,3H),3.59(s,3H),2.01(s,3H).
13 C NMR(126MHz,DMSO-d 6 )δ170.67,160.64,157.29,149.79,146.79,144.67,142.98,131.26,130.36,125.15,124.94,121.63,109.06,105.62,103.20,102.40,55.74,55.37,38.12,22.90。
EXAMPLE 6 preparation of Compound 6
(1) Raw material B 2 Preparation of
See example 5.
(2) Preparation of Compound 6
Mixing 132mg of B 2 Dissolved in 3mL of thionyl chloride solution, 128mg of 4-chloroaniline and 37. mu.L of trifluoroacetic acid were added. The reaction was stirred at 100 ℃ for 10 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. The organic layer was washed with 30mL of water and 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel Chromatography (CH) 2 Cl 2 30% MeOH: 1) purification yielded compound 6(80mg, 45%).
Physical state: brown solid.
Melting point: 209.3-210.4 ℃.
TLC:R f ＝0.36(CH 2 Cl 2 /MeOH＝20:1).
1 H NMR(500MHz,CDCl 3 )δ8.78(s,1H),8.47(s,1H),7.93(d,J＝9.2Hz,1H),7.30(dd,J＝9.2,2.8Hz,1H),7.16–7.13(m,2H),7.00(s,1H),6.97(d,J＝2.8Hz,1H),6.73–6.70(m,2H),4.50(d,J＝6.6Hz,2H),3.60(s,3H),2.01(s,3H).
13 C NMR(126MHz,DMSO-d 6 )δ170.79,157.47,149.86,144.68,144.51,142.62,131.38,129.35,125.21,125.07,123.43,121.75,117.71,102.93,100.00,55.76,38.07,22.85。
EXAMPLE 7 preparation of Compound 7
(1) Raw material B 3 Preparation of
1.61g A 3 Dissolved in dichloromethane, 67mg of cuprous chloride and 3.8mL of pyridine were added. The reaction was stirred at room temperature for 15 hours. The reaction mixture was then poured into 80mL of water and extracted with 150mL of dichloromethane. The organic layer was washed with 80mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) to give compound B 3 (985mg，54％)。
Physical state: yellow solid.
Melting point: 145.2-146.1 ℃.
TLC：R f ＝0.25(EtOAc).
1 H NMR(500MHz,CDCl 3 )δ11.42(s,1H),8.73(d,J＝9.0Hz,1H),8.48(s,1H),7.86(d,J＝2.4Hz,1H),7.53–7.50(m,1H),6.06(s,1H),3.64(q,J＝5.9Hz,2H),3.28(t,J＝5.7Hz,2H),1.97(s,3H).
13 C NMR(126MHz,CDCl 3 )δ202.69,170.50,159.83,138.32,135.18,130.57,128.43,123.17,122.70,39.70,34.47,23.33.
(2) Preparation of Compound 7
161mg of B 3 Dissolve in 3mL of thionyl chloride solution and add 109. mu.L of aniline and 44. mu.L of trifluoroacetic acid. The reaction was stirred at 100 ℃ for 14 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. Washed with 30mL of water and 30mL of saturated brineWashing organic layer, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, and subjecting the obtained crude product to silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) afforded compound 7(94mg, 48%).
Physical state: a pale yellow solid.
Melting point: 119.3-200.1 ℃.
TLC：R f ＝0.39(CH 2 Cl 2 /MeOH＝20:1).
1 H NMR(500MHz,DMSO-d 6 )δ8.76(s,1H),8.75(s,1H),8.51(t,J＝5.8Hz,1H),8.00(d,J＝8.9Hz,1H),7.94(d,J＝2.3Hz,1H),7.72–7.68(m,1H),7.21(t,J＝7.9Hz,2H),6.86(t,J＝7.3Hz,1H),6.70(d,J＝7.7Hz,2H),4.24(d,J＝5.9Hz,2H),1.84(s,3H).
13 C NMR(126MHz,DMSO-d 6 )δ170.62,152.99,147.35,145.29,143.44,132.04,130.83,130.06,129.72,125.09,124.90,123.39,120.74,116.74,38.12,22.91。
EXAMPLE 8 preparation of Compound 8
(1) Raw material B 3 Preparation of
See example 7.
(2) Preparation of Compound 8
Mixing 134mg of B 3 Dissolve in 3mL of thionyl chloride and add 127mg of 4-chloroaniline and 37. mu.L of trifluoroacetic acid. The reaction was stirred at 100 ℃ for 6 hours. The resulting mixture was then poured into 30mL of saturated sodium bicarbonate and extracted with 50mL of ethyl acetate. The organic layer was washed with 30mL of water and 30mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel Chromatography (CH) 2 Cl 2 Purification with MeOH ═ 30:1) afforded compound 8(90mg, 50%).
Physical state: yellow solid.
Melting point: 226.7-227.4 ℃.
TLC：R f ＝0.42(CH 2 Cl 2 /MeOH＝20:1).
1 H NMR(500MHz,CDCl 3 )δ8.81(s,1H),8.64(s,1H),7.97(d,J＝9.0Hz,1H),7.75(d,J＝2.3Hz,1H),7.58(dd,J＝8.9,2.3Hz,1H),7.18–7.15(m,2H),6.73–6.71(m,2H),6.68(t,J＝6.1Hz,1H),4.51(d,J＝6.6Hz,2H),2.01(s,3H).
13 C NMR(126MHz,DMSO-d 6 )δ170.66,152.94,147.22,144.33,142.99,132.02,131.19,130.25,129.50,125.63,124.97,123.99,123.15,117.93,38.07,22.89。
And (3) biological activity test:
human lung cancer cell line PC-9 cells were used as the test cell line (cells purchased from cell resource center of Shanghai Life sciences institute of Chinese academy of sciences).
Application example: inhibition of human lung cancer cell line PC-9 cell proliferation and survival
Materials: human lung cancer cell line PC-9; the tested drugs are: 10 μm; the cell culture method comprises the following steps: taking out PC-9 cells frozen in liquid nitrogen, unfreezing in warm water at 37 ℃, transferring the cell suspension into a 1.5mL centrifuge tube, placing the centrifuge tube in a centrifuge, centrifuging at 2000rpm for 10min, removing supernatant, adding 1mL RPMI 1640 complete culture solution, gently blowing and beating uniformly, adding the cell suspension into a culture dish, supplementing 2mL RPMI 1640 complete culture solution, placing the culture dish in 5% CO 2 And cultured in an incubator at 37 ℃. Cytotoxicity test: PC-9 cells were cultured at 8X 10 3 Inoculating the cells/well into a 96-well culture plate, culturing for 20h, sucking and removing the old culture medium, adding a compound with the concentration of 10 mu m in each well, additionally arranging a solvent control group and a blank control group, incubating in an incubator for 72h, carefully sucking and removing the culture medium, washing with PBS for 3 times, adding 90 mu L of 1640 culture medium without serum and phenol red and 10 mu L of MTT solution (5mg/mL) into each well, continuing to incubate for 5h, terminating the culture, carefully sucking and removing the culture solution in the 96-well plate, adding 150 mu L of DMSO solution into each well, and shaking for 10min in a dark place to fully dissolve the purple crystal; the absorbance (A) of each well was measured at a wavelength of 570nm with a multifunctional microplate reader, and the survival rate of the cells was calculated as follows: cell viability ═ 100% (test group a value/blank control group a value).
The activity parameters of the products obtained in examples 1 to 8 are shown in Table 1: survival was at a concentration of 10 μ M compound.
TABLE 1 antitumor Activity of the Compounds obtained in examples 1-8
The above description is only a preferred embodiment of the present invention, and all equivalent changes and modifications made in accordance with the claims of the present invention should be covered by the present invention.
Claims (4)
1. A preparation method of an oxidative coupling rearrangement product based on a tryptamine skeleton is characterized by comprising the following steps: dissolving a raw material B in thionyl chloride, adding any one of aniline, 3-methoxyaniline, 4-chloroaniline, 1-naphthylamine and methoxyaniline, adding trifluoroacetic acid, and reacting at 100 ℃ for 6-15h to obtain the oxidation coupling rearrangement product based on the tryptamine skeleton, which has the following structural general formula:
wherein R is 1 H, Cl or OMe, R 2 H, Cl or OMe;
the structural general formula of the raw material B is as follows:
wherein R is 1 H, Cl or OMe.
2. The method of claim 1, wherein: r in the raw material B 1 The preparation of H or OMe comprises the following steps: dissolving sodium periodate in water, and stirring for 1 hour at 0 ℃ to prepare a solution I; dissolving the raw material A in methanol to prepare a solution II; slowly adding the solution I into the solution II, reacting for 15 hours at room temperature, pouring the obtained mixture into water, and extracting for 2-3 times by using dichloromethane; separation of organic matterLayer, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure and the crude product purified by silica gel chromatography to give starting material B;
the structural general formula of the raw material A is
Wherein R is 1 H or OMe.
3. The method of claim 1, wherein: r in the raw material B 1 The preparation of Cl comprises the following steps: dissolving a raw material A in dichloromethane, and adding cuprous chloride and pyridine; the reaction was stirred at room temperature under an oxygen atmosphere, and the resulting mixture was diluted with dichloromethane and washed with water and saturated brine; separating the organic layer, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, and purifying the obtained crude product with silica gel chromatography to obtain raw material B;
the structural general formula of the raw material A is
Wherein R is 1 Is Cl.
4. A method according to claim 2 or 3, characterized in that: the eluent in the silica gel chromatography is CH 2 Cl 2 /MeOH＝30:1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110716979.2A CN113321594B (en) | 2021-06-28 | 2021-06-28 | Oxidative coupling rearrangement product based on tryptamine skeleton and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110716979.2A CN113321594B (en) | 2021-06-28 | 2021-06-28 | Oxidative coupling rearrangement product based on tryptamine skeleton and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113321594A CN113321594A (en) | 2021-08-31 |
| CN113321594B true CN113321594B (en) | 2022-08-12 |
Family
ID=77424845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110716979.2A Active CN113321594B (en) | 2021-06-28 | 2021-06-28 | Oxidative coupling rearrangement product based on tryptamine skeleton and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113321594B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWD181245S (en) * | 2015-11-26 | 2017-02-11 | 愛茉莉太平洋股份有限公司 | Dispenser |
| WO2019104199A1 (en) * | 2017-11-21 | 2019-05-31 | Regen Biopharma Inc. | Small molecule agonists and antagonists of nr2f6 activity |
| CN110835341B (en) * | 2019-11-29 | 2022-03-04 | 福州大学 | Tetrahydrocarboline skeleton-containing oxidative coupling rearrangement product and preparation method and application thereof |
-
2021
- 2021-06-28 CN CN202110716979.2A patent/CN113321594B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113321594A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108117507B (en) | Synthesis method and application of azaspiro cyclohexadienone | |
| CN110330500B (en) | Stereoselective synthesis method of 6 beta-hydroxy-7, 8-dihydro-morphine derivative | |
| CN113321594B (en) | Oxidative coupling rearrangement product based on tryptamine skeleton and preparation method and application thereof | |
| CN110835341B (en) | Tetrahydrocarboline skeleton-containing oxidative coupling rearrangement product and preparation method and application thereof | |
| CN112574198B (en) | Indolated derivative of tetrahydro-beta-carboline and preparation and application thereof | |
| CN108623530B (en) | 1,2, 8-oxo-diazacyclononane-9-thioketone derivative and synthetic method and application thereof | |
| CN110092786B (en) | Method for preparing evodiamine | |
| CN114736213B (en) | Preparation method of carboxyl-tetrachloro-fluorescein | |
| CN113603694B (en) | 1, 2-diketone compound and preparation method and application thereof | |
| CN112300118B (en) | Benzothiopyranone compound and preparation method and application thereof | |
| CN110790709B (en) | Dehydroabietic acid benzimidazole-2-benzenesulfonamide derivative and preparation method and application thereof | |
| CN108276420B (en) | 8, 13-dihydrobenzo [5,6] chromene [2,3-b ] indole compound and synthetic method thereof | |
| CN110759961B (en) | Ursolic acid indolyquinone amide derivatives and preparation method and application thereof | |
| CN113980082A (en) | Preparation method of 25-hydroxy steroid intermediate and preparation method of 25-hydroxy steroid | |
| CN109748809B (en) | Method for synthesizing 2-substituted amino-1, 4-naphthoquinone derivative | |
| CN113717135A (en) | Synthesis method of carbonyl substituted benzodihydropyran and benzodihydropyran compound | |
| CN115677456B (en) | Preparation method of cannabidiol | |
| US20230063754A1 (en) | Novel method for synthesizing decursin derivative | |
| CN109053513B (en) | Substituted naphthol compound and application thereof in antitumor drugs | |
| CN113292573B (en) | Indolizine chromogen ketone compound with anti-tumor activity and preparation method and application thereof | |
| CN109796353B (en) | Synthetic method of 5-aminolevulinic acid hydrochloride | |
| CN109776415B (en) | Preparation method of Roxadustat intermediate | |
| CN109467558B (en) | 1-hydropyrrolizine derivative and synthesis method and application thereof | |
| CN108358898B (en) | Para-naphthoquinone derivative with anticancer activity and synthesis method thereof | |
| CN116444505A (en) | Silybin sulfonamide derivative with anti-tumor activity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |